Past Newsletters
UCSF and I-SPY 2 Breast Cancer Researchers Develop Newly Redefined Breast Cancer Response Subtypes
Research scientists and statisticians from UC San Francisco have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients.
Drug Turns Cancer Gene Into "Eat Me" Flag for Immune System
UCSF-led study shows promising pre-clinical results in killing cancer cells resistant to current KRAS-targeted treatments.
“CAR Pooling” Screens Identify Most Effective Cancer Immunotherapy Cells
New approach by UCSF researchers analyzes how well different re-engineered T cells work against cancer.
How AI Found the Words to Kill Cancer Cells
Predictive model allows researchers to encode commands for cells to carry out.
Drug Targeting Tauopathies in Mice Reveals Sex Differences in Response
Microglia are cells that are central to both brain health as well as disease progression in many neurological conditions.
Enhancing Care for Thoracic Oncology Surgery Patients
Building on a decades-long reputation for innovation in thoracic surgery, UC San Francisco’s Thoracic Surgery and Oncology Clinic has improved the overall experience for patients undergoing lung and esophageal cancer treatment while continuing ...
Race-Based Equations May Lead to Under-Treatment of Lung Disease in Black Patients
Using race-based equations to evaluate lung disease -- a practice promoted in the 2019 guidelines of the American Thoracic Society -- may mean that severe lung disease in Black patients is classified as moderate disease, according to a UCSF-led study.
Aggressive Surgery Increases Survival with Low-Grade Brain Tumors
UCSF-Led study shows extensive resection results in longer survival for glioma patients
Cerebral Cavernous Malformation Treatments Relieve Disparate Symptoms
Two patients with severe yet different neurological symptoms were referred to UCSF for emergent neurosurgical evaluation. Both were found to have previously undiagnosed cerebral cavernous malformations (CCMs), but each patient’s treatment was unique.
First “Neuroprosthesis” Expands Vocabulary and Mobility for Man With Paralysis in New Milestone
The first “neuroprosthesis,” developed by UCSF researchers in 2021, translates brain signals from a man with severe paralysis directly into words that appear as text on a screen. Using this brain-machine interface, he can also move a robotic ...
Novel Metabolic Imaging Method Detects Prostate Cancer Aggressiveness
UCSF investigators have shown that adding an emerging metabolic imaging technique to MR–transrectal ultrasound fusion prostate biopsies makes it possible to detect the extent and aggressiveness of prostate cancer more accurately than ever.
International Conference Features UCSF Breast Cancer Experts
Breast cancer experts from UCSF Health presented new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most prestigious breast cancer conference.
Rethinking How Cancer Cells Evade Targeted Therapy
Glioblastomas (GBMs) are incurable brain tumors with a prognosis of about one-and-a half years on average. They are highly resistant to treatment and have defied all attempts at precision therapy.
UCSF Cancer Specialist Recognized with Luminary Award for Gastrointestinal Cancers
Alan P. Venook, MD, a renowned expert in colorectal and liver cancers, has been announced as one of the winners of the 2022 Luminary Awards in Gastrointestinal (GI) Cancers.
UCSF Researchers Uncover New Pathway for Molecular Cancer Drug Therapies
In a study published December 8, 2022 in Science, UCSF researchers Kevin Lou, an MD-PhD student, Luke Gilbert, PhD, and Kevan Shokat, PhD, reveal the discovery of a cellular uptake pathway important for larger molecules.